British Journal of Cancer - Table of Contents alert Volume 110 Issue 8

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 110, Issue 8 (1917-2164) Published online 15 April 2014 In this issue Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics & Genomics Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Tumour protein predicts response to chemo in oesophageal cancer patients  Patients with the most common type of oesophageal cancer are less likely to respond to chemotherapy when their tumours are high in a protein called leptin, according to research published in the British Journal of Cancer.  Click here to view the article. Clinical Studies Top First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC J J Ko, T K Choueiri, B I Rini, J-L Lee, N Kroeger, S Srinivas, L C Harshman, J J Knox, G A Bjarnason, M J MacKenzie, L Wood, U N Vaishampayan, N Agarwal, S K Pal, M-H Tan, S Y Rha, T Yuasa, F Donskov, A Bamias and D Y C Heng Br J Cancer 2014 110: 1917-1922; advance online publication, April 1, 2014; 10.1038/bjc.2014.25 Abstract | Full Text A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer R M Glasspool, R Brown, M E Gore, G J S Rustin, I A McNeish, R H Wilson, S Pledge, J Paul, M Mackean, G D Hall, H Gabra, S E R Halford, J Walker, K Appleton, R Ullah and S Kaye Br J Cancer 2014 110: 1923-1929; advance online publication, March 18, 2014; 10.1038/bjc.2014.116 Abstract | Full Text Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer D J Pinato, R J Shiner, M J Seckl, J Stebbing, R Sharma and F A Mauri Br J Cancer 2014 110: 1930-1935; advance online publication, March 25, 2014; 10.1038/bjc.2014.145 Abstract | Full Text A multicentre randomised controlled trial of reciprocal lung cancer peer review and supported quality improvement: results from the improving lung cancer outcomes project G K Russell, S Jimenez, L Martin, R Stanley, M D Peake and I Woolhouse Br J Cancer 2014 110: 1936-1942; advance online publication, March 20, 2014; 10.1038/bjc.2014.146 Abstract | Full Text Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy T Hamada, Y Nakai, H Yasunaga, H Isayama, H Matsui, N Takahara, T Sasaki, K Takagi, T Watanabe, H Yagioka, H Kogure, T Arizumi, N Yamamoto, Y Ito, K Hirano, T Tsujino, M Tada and K Koike Br J Cancer 2014 110: 1943-1949; advance online publication, March 18, 2014; 10.1038/bjc.2014.131 Abstract | Full Text Adaptive designs for clinical trials assessing biomarker-guided treatment strategies J Wason, A Marshall, J Dunn, R C Stein and N Stallard Br J Cancer 2014 110: 1950-1957; advance online publication, March 25, 2014; 10.1038/bjc.2014.156 Abstract | Full Text Translational Therapeutics Top Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells Q Yang, J Huang, Q Wu, Y Cai, L Zhu, X Lu, S Chen, C Chen and Z Wang Br J Cancer 2014 110: 1958-1967; advance online publication, March 18, 2014; 10.1038/bjc.2014.136 Abstract | Full Text Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies D Tural, S Serdengecti, F Demirelli, T Öztürk, S İlvan, H Turna, M Özgüroglu and E Büyükünal Br J Cancer 2014 110: 1968-1976; advance online publication, March 4, 2014; 10.1038/bjc.2014.72 Abstract | Full Text Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules J Murray, H Thomas, P Berry, S Kyle, M Patterson, C Jones, G Los, Z Hostomsky, E R Plummer, A V Boddy and N J Curtin Br J Cancer 2014 110: 1977-1984; advance online publication, February 20, 2014; 10.1038/bjc.2014.91 Abstract | Full Text Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer S Suzuki, K Kaira, Y Ohshima, N S Ishioka, M Sohda, T Yokobori, T Miyazaki, N Oriuchi, H Tominaga, Y Kanai, N Tsukamoto, T Asao, Y Tsushima, T Higuchi, T Oyama and H Kuwano Br J Cancer 2014 110: 1985-1991; advance online publication, March 25, 2014; 10.1038/bjc.2014.142 Abstract | Full Text Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells Y Zou, F Li, W Hou, P Sampath, Y Zhang and S H Thorne Br J Cancer 2014 110: 1992-1999; advance online publication, March 18, 2014; 10.1038/bjc.2014.140 Abstract | Full Text Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model A Bhardwaj, S Singh, S K Srivastava, S Arora, S J Hyde, J Andrews, W E Grizzle and A P Singh Br J Cancer 2014 110: 2000-2010; advance online publication, March 18, 2014; 10.1038/bjc.2014.141 Abstract | Full Text Molecular Diagnostics Top Leucine-rich repeat-containing G-protein-coupled receptor 5 is associated with invasion, metastasis, and could be a potential therapeutic target in human gastric cancer H Q Xi, A Z Cai, X S Wu, J X Cui, W S Shen, S B Bian, N Wang, J Y Li, C R Lu, Z Song, B Wei and L Chen Br J Cancer 2014 110: 2011-2020; advance online publication, March 4, 2014; 10.1038/bjc.2014.112 Abstract | Full Text Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer H He, Z Shen, H Zhang, X Wang, Z Tang, J Xu and Y Sun Br J Cancer 2014 110: 2021-2029; advance online publication, March 11, 2014; 10.1038/bjc.2014.93 Abstract | Full Text ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer K Shimizu, K Kaira, Y Tomizawa, N Sunaga, O Kawashima, N Oriuchi, H Tominaga, S Nagamori, Y Kanai, M Yamada, T Oyama and I Takeyoshi Br J Cancer 2014 110: 2030-2039; advance online publication, March 6, 2014; 10.1038/bjc.2014.88 Abstract | Full Text CD74: a new prognostic factor for patients with malignant pleural mesothelioma C Otterstrom, A Soltermann, I Opitz, E Felley-Bosco, W Weder, R A Stahel, F Triponez, J H Robert and V Serre-Beinier Br J Cancer 2014 110: 2040-2046; advance online publication, March 4, 2014; 10.1038/bjc.2014.117 Abstract | Full Text Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma N Sunaga, K Kaira, Y Tomizawa, K Shimizu, H Imai, G Takahashi, S Kakegawa, Y Ohtaki, T Nagashima, N Kasahara, O Kawashima, T Hisada, R Saito and M Yamada Br J Cancer 2014 110: 2047-2053; advance online publication, February 27, 2014; 10.1038/bjc.2014.110 Abstract | Full Text Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer I Balgkouranidou, M Chimonidou, G Milaki, E G Tsarouxa, S Kakolyris, D R Welch, V Georgoulias and E S Lianidou Br J Cancer 2014 110: 2054-2062; advance online publication, March 18, 2014; 10.1038/bjc.2014.104 Abstract | Full Text Lack of correlation of stem cell markers in breast cancer stem cells Y Liu, R Nenutil, M V Appleyard, K Murray, M Boylan, A M Thompson and P J Coates Br J Cancer 2014 110: 2063-2071; advance online publication, February 27, 2014; 10.1038/bjc.2014.105 Abstract | Full Text Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c M K Nygren, C Tekle, V A Ingebrigtsen, R Mäkelä, M Krohn, M R Aure, C E Nunes-Xavier, M Perälä, T Tramm, J Alsner, J Overgaard, J M Nesland, E Borgen, A-L Børresen-Dale, Ø Fodstad, K K Sahlberg and S-K Leivonen Br J Cancer 2014 110: 2072-2080; advance online publication, February 27, 2014; 10.1038/bjc.2014.113 Abstract | Full Text Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer K Malinowsky, U Nitsche, K-P Janssen, F G Bader, C Späth, E Drecoll, G Keller, H Höfler, J Slotta-Huspenina and K-F Becker Br J Cancer 2014 110: 2081-2089; advance online publication, March 11, 2014; 10.1038/bjc.2014.100 Abstract | Full Text Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model R Fox, S Berhane, M Teng, T Cox, T Tada, H Toyoda, T Kumada, C Kagebayashi, S Satomura and P J Johnson Br J Cancer 2014 110: 2090-2098; advance online publication, April 1, 2014; 10.1038/bjc.2014.130 Abstract | Full Text Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer M Brown, J-A Roulson, C A Hart, T Tawadros and N W Clarke Br J Cancer 2014 110: 2099-2108; advance online publication, March 4, 2014; 10.1038/bjc.2014.99 Abstract | Full Text A novel staging model to classify oesophageal squamous cell carcinoma patients in China H Tan, H Zhang, J Xie, B Chen, C Wen, X Guo, Q Zhao, Z Wu, J Shen, J Wu, X Xu, E Li, L Xu and X Wang Br J Cancer 2014 110: 2109-2115; advance online publication, February 25, 2014; 10.1038/bjc.2014.101 Abstract | Full Text Biliverdin’s regulation of reactive oxygen species signalling leads to potent inhibition of proliferative and angiogenic pathways in head and neck cancer J Zheng, D A Nagda, S A Lajud, S Kumar, A Mouchli, O Bezpalko, B W O'Malley, Jr and D Li Br J Cancer 2014 110: 2116-2122; advance online publication, February 25, 2014; 10.1038/bjc.2014.98 Abstract | Full Text Genetics & Genomics Top LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk S M Tajuddin, A F S Amaral, A F Fernández, S Chanock, D T Silverman, A Tardón, A Carrato, M García-Closas, B P Jackson, E G Toraño, M Márquez, R G Urdinguio, R García-Closas, N Rothman, M Kogevinas, F X Real, M F Fraga, N Malats and for the Spanish Bladder Cancer/EPICURO Study investigators Br J Cancer 2014 110: 2123-2130; advance online publication, March 4, 2014; 10.1038/bjc.2014.67 Abstract | Full Text Aza-deoxycytidine induces apoptosis or differentiation via DNMT3B and targets embryonal carcinoma cells but not their differentiated derivatives P Wongtrakoongate, J Li and P W Andrews Br J Cancer 2014 110: 2131-2138; advance online publication, March 6, 2014; 10.1038/bjc.2014.128 Abstract | Full Text Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network A Borley, T Mercer, M Morgan, P Dutton, P Barrett-Lee, M Brunelli and B Jasani Br J Cancer 2014 110: 2139-2143; advance online publication, April 1, 2014; 10.1038/bjc.2014.147 Abstract | Full Text ERRβ signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells D Sengupta, D K Bhargava, A Dixit, B S Sahoo, S Biswas, G Biswas and S K Mishra Br J Cancer 2014 110: 2144-2158; advance online publication, March 25, 2014; 10.1038/bjc.2014.53 Abstract | Full Text Prognostic impact of genomic instability in colorectal cancer T S Hveem, M A Merok, M E Pretorius, M Novelli, M S Bævre, O H Sjo, N Clinch, K Liestøl, A Svindland, R A Lothe, A Nesbakken and H E Danielsen Br J Cancer 2014 110: 2159-2164; advance online publication, March 18, 2014; 10.1038/bjc.2014.133 Abstract | Full Text Advertisement Don't miss out! Discover which British Journal of Cancer articles your colleagues are reading - view the top ten now.   Top Ten Articles Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.